When was Stilla Technologies founded?

Stilla Technologies was founded in 2013 and raised its 1st funding round 3 years after it was founded.

Where is Stilla Technologies located?

Stilla Technologies is headquartered in Villejuif, France.

Who is the current CEO of Stilla Technologies?

Remi Dangla and Philippe M s of Stilla Technologies. Remi Dangla has also founded 1 company.

How many employees does Stilla Technologies have?

As of Jul 31, 2026, the latest employee count at Stilla Technologies is 83.

Is Stilla Technologies a funded company?

Stilla Technologies is a funded company, having raised a total of $53.1M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 29, 2016.

When was the latest funding round of Stilla Technologies?

Stilla Technologies' latest funding was a $***** Conventional Debt round on Nov 23, 2021, with participation from 0 investor.

Where does Stilla Technologies rank among its competitors?

Stilla Technologies ranks 1st amongst 85 active competitors, of which 18 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Igenesis, which secured an undisclosed amount in Mar, 2022.

Who are the top competitors of Stilla Technologies?

Stilla Technologies' top competitors include NeuMoDx, GenMark Diagnostics and Bigtec Labs. Among them, Igenesis secured the most recent funding round in March, 2022.

Stilla Technologies - 2026 Company Profile, Team, Funding & Competitors

Stilla Technologies is an acquired company based in Villejuif (France), founded in 2013 by Remi Dangla and Clement Gay. It operates as a Developer of digital PCR solution for research. Stilla Technologies has raised $53.1M in funding from investors like Illumina Ventures, Idinvest Partners and Kurma Partners. The company has 85 active competitors, including 18 funded and 11 that have exited. Its top competitors include companies like NeuMoDx, GenMark Diagnostics and Bigtec Labs.

Company Details

Developer of digital PCR solution for research. The system works on the principle of Crystal Digital PCR in a compact and reliable digital PCR solution with a single consumable. The device is assisted by Crystal Miner software for analyzing the generated data and identifying positive and negative droplets for all 3 fluorescence channels.

Website: stillatechnologies.com
Social

Key Metrics

Founded Year

2013

Location

Villejuif, France

Stage

Acquired

Total Funding

$53.1M in 6 rounds

Latest Funding Round

Conventional Debt, Nov 23, 2021, $*****

Investors

Illumina Ventures & 12 more

Ranked

1^st among 85 active competitors

Employee Count

83 as on Jul 31, 2026

Similar Companies

GenMark Diagnostics & 49 more

Exit Details

Acquired by Bio Rad (Feb 14, 2025)

View Stilla Technologies' full profile

Stilla Technologies got acquired by Bio Rad on Feb 14, 2025.

Click here to take a look at Stilla Technologies's acquisition in detail

Stilla Technologies has raised a total funding of $53.1M over 6 rounds. Its first funding round was on Nov 29, 2016. Stilla Technologies has 13 institutional investors.

Here is the list of recent funding rounds of Stilla Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 23, 2021	8053117	Conventional Debt	9671829	4347592	1424376	7602534
Nov 23, 2021	1983392	Series B	2037693	2486883	3528322	Illumina Ventures & 7 more
Feb 05, 2020	2474067	Series B	6553965	8976109	Illumina Ventures & 6 more	1190409

Access funding benchmarks and valuations. Sign up today!

View details of Stilla Technologies's funding rounds and investors

The founders of Stilla Technologies are Remi Dangla and Clement Gay. Remi Dangla and Philippe M are the CEOs of Stilla Technologies.

Here are the details of Stilla Technologies' key team members:

Remi Dangla: Co-Founder & CEO of Stilla Technologies.
Contact Info: 1 phone number
Clement Gay: Co-Founder of Stilla Technologies.
Philippe M: CEO of Stilla Technologies.

View details of Stilla Technologies's Founder profiles and Board Members

Stilla Technologies' employee count trend

Stilla Technologies has 83 employees as of Jul 26. Here is Stilla Technologies's employee count trend over the years:

Employee count trend for Stilla Technologies

Uncover Stilla Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Stilla Technologies include NeuMoDx, GenMark Diagnostics and Bigtec Labs. Here is the list of Top 10 competitors of Stilla Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Stilla Technologies 2013, Villejuif (France), Acquired	Developer of digital PCR solution for research	$53.1M	Partech Partners, Casdin Capital & 11 others	64/100
2nd	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Arboretum Ventures, Wolverine Venture Fund ... & 3 others	58/100
3rd	GenMark Diagnostics 1993, San Diego (United States), Acquired	Provider of instruments and test panels for multiplexed molecular diagnostics	$8.56M	SLR Investment Corp, VIDANT Capital	49/100
4th	Bigtec Labs 2000, Bengaluru (India), Funding Raised	Developer of point-of-care solutions for nucleic acid amplification tests	-	C-CAMP, Grand Challenges Canada & 3 others	46/100
5th	Silicon Biosystems 1999, Bologna (Italy), Acquired	Developer of lab on a chip technologies for miniaturized cell-biology testing	$25.5M	Indaco Venture Partners, Innogest Capital ... & 1 others	46/100
6th	n6 Tec 2021, Pleasanton (United States), Unfunded	Developer of a thermocycling technology for DNA amplification and sequencing	-	-	43/100
7th	Biomeme 2013, Philadelphia (United States), Series A	Developer of a smartphone-based DNA detection platform	$6.2M	Ben Franklin Technology Partners, SeedFord Partners ... & 9 others	42/100
8th	Accugenomics 2010, Wilmington (United States), Unfunded	Molecular diagnostics company specializing in NGS quality control standards and assays	-	-	40/100
9th	Prominex 2016, San Diego (United States), Series A	Provider of point-of-care molecular diagnostic solution	$4M	Casdin Capital, JLABS	40/100
10th	Igenesis 2015, Shanghai (China), Series C	Provider of automated PCR analysis platfrom	$13M	Morningside, Shanghai Kehua Bio-engineering ... & 5 others	39/100